^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HLX55

    i
    Other names: HLX55, HLX-55, KTN0216, KTN 0216, humanized IgG2 monoclonal antibody
    Associations

    News

    Trials
    Company:
    Fosun Pharma
    Drug class:
    c-MET inhibitor
    Related drugs:
    Associations

    News

    Trials
    4years
    Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status (clinicaltrials.gov)
    P1, N=98, Recruiting, Henlix, Inc | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET overexpression • MET mutation
    |
    HLX55
    over4years
    Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status (clinicaltrials.gov)
    P1, N=98, Not yet recruiting, Henlix, Inc | Initiation date: Nov 2019 --> Apr 2020
    Clinical • Trial initiation date
    |
    KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET amplification • MET exon 14 mutation • MET overexpression • MET mutation
    |
    HLX55